Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Heart Matters

SBP target of lower than 120 mmHg reduces risk of CV events in T2DM

Shawna Nesbitt
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    AHA 2024 - The BPROAD study investigated whether intensive SBP reduction (<120 mmHg) vs. standard SBP reduction (<140 mmHg) offers greater protection for CV outcomes in patients with T2DM. Discussant Shawna Nesbitt reviews the results.

  • Educational information

    This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.

  • Faculty

    Shawna Nesbitt, MD is the John C. Vanatta III Professor in the Department of Internal Medicine at UT Southwestern Medical Center, Dallas, TX, US. 

  • Disclaimer

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Release date: 18 November 2024

Recommended
Details
Presenters
Comments
  • Overview

    AHA 2024 - The BPROAD study investigated whether intensive SBP reduction (<120 mmHg) vs. standard SBP reduction (<140 mmHg) offers greater protection for CV outcomes in patients with T2DM. Discussant Shawna Nesbitt reviews the results.

  • Educational information

    This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.

  • Faculty

    Shawna Nesbitt, MD is the John C. Vanatta III Professor in the Department of Internal Medicine at UT Southwestern Medical Center, Dallas, TX, US. 

  • Disclaimer

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Release date: 18 November 2024

Schedule9 Dec 2024